In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Grail closes $300mm Series C round

Executive Summary

Cancer diagnostics company Grail Inc. raised $300mm through its Series C round. Ally Bridge Group, Hillhouse Capital Group, and 6 Dimensions Capital co-led and were joined by Blue Pool Capital, China Merchant Securities International, CRF Investment, HuangPu River Capital, ICBC International, Sequoia Capital China, and WuXi NextCODE. To date, Grail has raised over $1.5bn through three venture rounds to support continued development of its molecular diagnostics tools.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register